Menu Close

Welcome to the laboratory of Dr. Adrian Lee and Dr. Steffi Oesterreich!

20231116_LabLuncheon_1
LeeOesterreich Party_3
LOLabTour
LOLab_2021
LeeOesterreich_GroupPhoto_20200913_crop
Pittsburgh_DanielDBrown_07
Pittsburgh cityview
11
Pittsburgh_DanielDBrown_00b
Pittsburgh_DanielDBrown_23_b
previous arrow
next arrow

The Lee/Oesterreich lab studies the molecular basis of breast cancer development and resistance to therapy, with the goal to improve precision medicine and outcomes for breast cancer patients. The laboratory employs a systems biology approach, utilizing a combination of single cell and bulk sequencing, computational methods and biological models to identify and validate new drivers and therapeutic targets. Hypotheses are tested in vitro and in vivo and then moved to clinical trials.

The majority of studies incorporate analysis of human specimens, in collaboration with a large network of clinicians and nurses. This includes computational analysis and modeling of large biomedical and genomic datasets including electronic health record data.

A major focus of the laboratory is identifying mechanisms of resistance to endocrine therapy, and new approaches to blocking breast cancer metastasis through precision medicine. This includes the study of estrogen receptor (ESR1) mutations and fusions and synergism with growth factor pathways. A special focus is on the understanding of invasive lobular cancer (ILC), the second most common but understudied histological subtype of breast cancer.

The laboratory has a very strong training environment, with attention to each individuals’ successful career development. One of the top priorities is to maintain a healthy lab environment, ensuring high productivity and rigor.

The Lee/Oesterreich Lab at our annual retreat, August 2019